Table 1 Clinicopathological characteristics of 77 patients according to the WHO 2017 classification.
From: Molecular classification of follicular thyroid carcinoma based on TERT promoter mutations
MI-FTC (n = 39) | EA-FTC (n = 24) | WI-FTC (n = 14) | P for trend | |
|---|---|---|---|---|
Sex (n, %) | ||||
Female | 31 (79.5) | 17 (70.8) | 11 (78.6) | 0.767 |
Male | 8 (20.5) | 7 (29.2) | 3 (21.4) | |
Age, year (mean, SD) | 40.1 (13.76) | 42.1 (18.7) | 48.5 (12.2) | 0.172* |
Size | ||||
Mean, cm (mean, SD) | 3.26 (1.59) | 4.08 (1.68) | 4.65 (3.37) | 0.130* |
4 cm or less | 28 (71.8) | 14 (58.3) | 9 (64.3) | 0.444 |
More than 4 cm | 11 (28.2) | 10 (41.7) | 5 (35.7) | |
Gross ETE | ||||
Absent | 39 (100.0) | 23 (95.8) | 12 (85.7) | 0.023 |
Present | 0 (0.0) | 1 (4.2) | 2 (14.3) | |
Distant metastasis | ||||
Absent | 39 (100.0) | 22 (91.7) | 8 (57.1) | <0.001 |
Present | 0 (0.0) | 2 (8.3) | 6 (42.9) | |
TERT promoter mutations | ||||
Wild type | 35 (89.7) | 19 (79.2) | 9 (64.3) | 0.033 |
Mutation | 4 (10.3) | 5 (20.8) | 5 (35.7) | |
AJCC/TNM 8th stage | ||||
Stage I | 39 (100.0) | 18 (75.0) | 8 (57.1) | <0.001 |
Stage II | 0 (0.0) | 4 (16.7) | 5 (35.7) | |
Stage III/IV | 0 (0.0) | 2 (8.3) | 1 (7.1) | |
Surgical extent | ||||
Total | 16 (41.0) | 17 (70.8) | 13 (92.9) | <0.001 |
Subtotal or lobectomy | 23 (59.0) | 7 (29.2) | 1 (7.1) | |
Cumulative RAI dose | ||||
Less than 100 mCi | 24 (61.5) | 9 (37.5) | 1 (7.1) | <0.001 |
100 mCi or more | 15 (38.5) | 15 (62.5) | 13 (92.9) | |
